SMA Combination denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sma combination are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies SMA Combination Therapy as Duplicate Therapy

Spinal muscular atrophy (SMA) is now treated with multiple approved disease-modifying therapies, including agents that work via distinct but sometimes overlapping biological mechanisms. BCBS may issue a duplicate-therapy denial when a member is already receiving one approved SMA treatment and their prescriber requests a second, arguing that the two therapies address the same target or produce similar clinical effects. This denial is clinically complex because the evidence base for combination SMA therapy is actively evolving and varies by SMA type and patient profile.

## Why This Denial Is Appealable

The central argument against a duplicate-therapy denial for SMA combination treatment is mechanistic distinction: the approved SMA therapies act on different molecular pathways. Whether combination use is appropriate for your specific SMA type and clinical situation is a question your neurologist is best positioned to answer, drawing on your detailed chart and the current state of published evidence. Obtain the exact BCBS coverage policy language that defines "duplicate therapy" and the specific criteria used to apply that label to your request. Your neurologist's letter should directly rebut each stated basis for the duplicate classification. Request that BCBS provide the clinical evidence it relied on in reaching the determination, as ERISA requires disclosure of those materials.

## Federal Appeal Rights

ERISA §503 entitles employer-plan members to a full-and-fair review, including access to all documents the plan relied on. ACA §2719 provides independent external review rights once internal appeals are exhausted. External review is particularly important in SMA combination cases because an independent clinical expert — not a BCBS employee — reviews the evidence. The external review window is typically around four months from the final internal denial; confirm the exact deadline on your denial notice. Expedited appeal is available if delay poses a serious risk to health.

## Concrete Appeal Steps

1. Request the denial rationale, the BCBS coverage policy applied, and all clinical evidence BCBS used, in writing. 2. Have your neurologist prepare a detailed medical-necessity letter explaining the mechanistic distinction between the two therapies and the clinical rationale for combination use in your specific case. 3. File a Level 1 internal appeal with the neurologist's letter and all supporting chart documentation. 4. If Level 1 is denied, escalate to Level 2 or proceed to external review, where an independent SMA specialist may review the file. 5. Contact the manufacturer's patient-assistance and reimbursement support programs, which often provide appeal-support letters and clinical evidence packages.

## Documentation to Gather

• Neurologist's letter specifically addressing the mechanistic distinction between the two SMA therapies and the clinical rationale for your combination regimen.
• Complete SMA diagnosis documentation: genetic confirmation, SMA type classification, functional assessment per your chart.
• Treatment history: dates, dosing records, and documented clinical response for the currently approved therapy already in use.
• Current functional status assessments from your neurologist and any allied health team members (physical therapy, pulmonology).
• Any relevant published clinical guidance from the applicable neurology society or SMA specialist organizations (cite by organization name, not specific statistics).

## Criteria-Mapping Framework

Identify every basis BCBS used to call this combination "duplicate." For each basis, your rebuttal should cite: the specific mechanistic or pharmacological distinction your neurologist documents, the clinical evidence organization that supports combination use, and the specific chart finding that makes combination therapy appropriate for your case. Structure the appeal letter so each denial basis is addressed in a labeled section.